PRAMOMOLECULAR   is developing novel gene silencing therapies for the treatment of currently "incurable" diseases. Our covalently linked, lipid-based delivery molecules transport nucleic acid-based drugs (NABDs) into lung, heart and pancreatic cells in vivo. Using our "self-delivering siRNAs", which are a highly innovative class of drugs, we can efficiently down-regulate disease-causing proteins such as mutated or over-expressed proteins. This is of great interest because siRNAs can downregulate any disease-causing protein.

The goal of PRAMOMOLECULAR is to provide well-tolerated and effective therapeutics to patients with serious diseases. Our first drug candidates target diseases such as non-small cell lung cancer (NSCLC), pancreatic ductal adenocarcinoma (PDAC) and heart failure.

Beside developing our own drug candidates, we are also interested in co-developing and licensing our delivery technology to other developers of NABDs for specific applications.